FDG-PET in diagnosis, staging and follow-up of malignant melanoma

Year 2007, Volume: 22 Issue: 2, 88 - 94, 01.03.2007

Ayşe Mudun

Abstract

In this review article, the use of recent technology Flour18deoxyglucose Positron Emission Tomography (FDG-PET) in melanoma has been discussed. Studies in the medical literature regarding the use of FDG PET in early melanoma, staging of melanoma, sentinel lymph node detection, local recurrence and in transit metastasis, distant metastasis and restaging were reviewed and evaluated. Treatment evaluation with PET, recent developements in new PET radiopharmaceuticals and use of PET probe in melanoma has been quoted.

Keywords

Melanoma, Diagnosis, Neoplasm Staging, Positron-Emission Tomography, Fluorodeoxyglucose F18

Melanomun tanı, evreleme ve takibinde FDG-PET'in değeri

Abstract

Bu yazıda, son yıllarda onkolojide çeşitli tümörlerin tanı ve takibinde sıkça kullanılan Flor18-Deoksi-Glukoz Pozitron Emisyon Tomografinin (FDG-PET) melanomda kullanımı anlatıldı. Melanomun erken tanısında, hastalığın evrelenmesinde, sentinel lenf düğümünün araştırılmasında, lokal nüks ve intransit metastazlarda, uzak metastazların gösterilmesinde ve nüks durumunda yeniden evrelemede PET ile yapılmış çalışmalar ve sonuçları değerlendirildi. Tedaviye yanıt ölçümünde PET'in yeri, ayrıca yeni radyofarmasötiklerin melanomda kullanılabilirliği ve PET probla ilgili gelişmeler aktarıldı.

Keywords

Floro-deoksi-glukoz F18/tanısal kullanım, melanom/tanı, neoplazi evreleme, PET

References

• 1. Kim CJ, Reintgen DS, Balch CM; AJCC Melanoma Staging Committee. The new melanoma staging system. Cancer Control 2002;9(1):9-15.
• 2. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006;47(6):957-67.
• 3. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991;67(6):1544-50.
• 4. Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol 2005;89(10):1265-9.
• 5. Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 2006;32(7):780-4.
• 6. Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 2005;140(2):193-9.
• 7. Chao C, McMasters KM. Update on the use of sentinel node biopsy in patients with melanoma: who and how. Curr Opin Oncol 2002;14(2):217-20.
• 8. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultras o n o g r a p h y. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995c;131(12):1394-8.
• 9. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64(3):181-9.
• 10. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16(5):1770-6.
• 11. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41(9):1491-4.
• 12. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77(4):237-42.
• 13. Wagner JD, Schauwecker D, Davidson D, Coleman JJ, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients u n d e rgoing sentinel node biopsy. J Clin Oncol 1999;17(5):1508-15.
• 14. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19(10):2674-8.
• 15. Longo MI, Lázaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003;29(3):245-8.
• 16. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucosepositron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29(8):662-4.
• 17. Hafner J, Schmid MH, Kempf W, Burg G, Künzi W, Meuli-Simmen C, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150(4):677-86.
• 18. Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004;14(2):141-5.
• 19. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104(3):570-9.
• 20. Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34(4):242-53.
• 21. Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, et al. Contribution of whole body F-18- FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study. Nuklearmedizin 2000;39(3):56-61.
• 22. Krug B, Dietlein M, Groth W, Stützer H, Psaras T, Gossmann A, et al. Fluor- 1 8 - f l u o r o d e o x y g l u c o s e positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol 2000;41(5):446-52.
• 23. Aydin A, Yu JQ, Zhuang H, Alavi A. Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma. Clin Nucl Med 2005;30(9):606-7.
• 24. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005;43(1):23-33.
• 25. Finkelstein SE, Carrasquillo JA, Hoffman JM, Galen B, Choyke P, White DE, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 2004;11(8):731-8.
• 26. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on s u rgical decision making. Clin Nucl Med 2003;28(12):961-5.
• 27. Mijnhout GS, Comans EF, Raijmakers P, Hoekstra OS, Teule GJ, Boers M, et al. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002;23(5):475-81.
• 28. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89(5):1019-25.
• 29. Mercier GA, Alavi A, Fraker DL. FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clin Nucl Med 2001;26(10):832-6.
• 30. Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F. Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res 2001;96(1):120-6.